ScholarIQanswers from OpenAlex & ORCID
Richard P. Baum
ResearcherPublications, citations & collaboration network
Richard P. Baum is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard P. Baum have?
ScholarIQindexed works
Richard P. Baum has 625 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard P. Baum have?
ScholarIQcitation count
Richard P. Baum has 25,294 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard P. Baum?
ScholarIQh-index
Richard P. Baum has an h-index of 73 in OpenAlex.
What is the i10-index of Richard P. Baum?
ScholarIQi10-index
Richard P. Baum has an i10-index of 239 in OpenAlex.
What is the ORCID of Richard P. Baum?
ScholarIQorcid
The ORCID for Richard P. Baum is on the source record.
What is the OpenAlex record for Richard P. Baum?
ScholarIQopenalex
The OpenAlex for Richard P. Baum is on the source record.
What are the most-cited papers on Richard P. Baum?
ScholarIQmost cited works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand, Marianne E. Pavel, Richard P. Baum, Dieter Hörsch, M. Sue O’Dorisio, T. M. O’Dorisiol, James R. Howe, Marta Cremonesi, Dik J. Kwekkeboom
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei, Mark Kidd, Giovanni Paganelli, Chiara Maria Grana, Ignat Drozdov, Marta Cremonesi, Christopher Lepensky, Dik J. Kwekkeboom, Richard P. Baum, Eric P. Krenning, Irvin M. Modlin
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, Inés Margalet, Philippe Ruszniewski, Eric P. Krenning, on behalf of the NETTER-1 Study Group
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Richard P. Baum, Murat Fani Bozkurt, Johannes Czernin, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Laßmann, Felix M. Mottaghy, Wim J.G. Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Hans-Jürgen Wester, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Herrmann